Otwillo 44.44 IU/mL, nasal spray solution clinical trials

LONG-TERM INTERVENTIONAL FOLLOW-UP STUDY UP TO 4 YEARS OF AGE OF CHILDREN WITH PRADER-WILLI SYNDROME INCLUDED IN THE OTBB3 CLINICAL TRIAL AND COMPARISON WITH AN UNTREATED COHORT OF CHILDREN WITH PRADER-WILLI SYNDROME (OTBB3 FOLLOW-UP)

This study is looking at children with Prader-Willi Syndrome who took part in an earlier trial. Researchers want to see how they are doing up to four years later, especially regarding any health changes and how their previous treatment might have helped, compared to children who didn't receive that treatment.